Drug Combination Therapy
Drug Combination Therapy - Related Videos
01:28
Drug Therapy
0 Views •
2025
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations. Antianxiety Medications
11:28
3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
0 Views •
Cited by 7 •
2017
This protocol describes the fabrication of elastic 3D macroporous microcryogels by integrating microfabrication with cryogelation technology. Upon loading with cells, 3D microtissues are generated, which can be readily injected in vivo to facilitate regenerative therapy or assembled into arrays for in vitro high-throughput drug screening.
02:50
Combination Therapies and Personalized Medicine
0 Views •
2021
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment. The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50
Combination Therapies and Personalized Medicine
0 Views •
2023
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment. The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
04:19
Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model
0 Views •
2025
This video demonstrates an assay to evaluate the effectiveness of oral combined antiretroviral therapy (oral cART) in a human immunodeficiency virus-1 (HIV-1)-infected humanized mouse model. A combination of drugs targeting HIV-1, including nucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors, is administered along with a nutritional supplement and antibiotics. Following the consumption of this mixture by the humanized mice infected with HIV-1, the effective...
FAQs
Researchers compare the observed effect of two medicines with the effects expected from each medicine alone. An additive result reflects a combined effect consistent with those individual activities, whereas synergy indicates a stronger-than-expected response. Antagonism means that one medicine reduces the effect of the other. These distinctions help determine whether a proposed combination merits further study.
Medicines directed at different molecular pathways can disrupt complementary processes that tumors require for growth. This strategy may also reduce the likelihood that resistance to one mechanism will eliminate the entire treatment effect. In cancer research, pathway selection therefore influences both tumor control and the durability of responses, although the resulting interaction can still be beneficial, neutral, or antagonistic.
Biomarkers help researchers identify patients whose tumors have features associated with response to particular medicines or combinations. This approach supports more selective treatment design by linking molecular characteristics with likely benefit. It can also limit unnecessary adverse effects when a patient is less likely to respond, making biomarker-guided selection important in both study development and clinical evaluation.
Evaluation commonly progresses from cell-based studies to animal models and then clinical trials. Researchers examine whether the medicines produce the intended combined effect while also assessing dose, timing, toxicity, and interactions. Findings from earlier stages inform later testing, helping determine whether the combination has sufficient activity and an acceptable safety profile for continued development.
Dose and timing can influence both the strength of tumor control and the toxicity experienced with a combination. Researchers therefore do not assess only which medicines are paired; they also examine how much of each agent is given and when. These variables can alter interactions between treatments and are evaluated in preclinical studies and clinical trials.
Cancer researchers may investigate combinations when stronger or more durable tumor control is needed, when complementary processes can be disrupted, or when resistance to a single mechanism is a concern. Successful designs can expand treatment options and improve control of tumors. Clinical and preclinical results also reveal whether benefits are offset by toxicity or unfavorable drug interactions.